What is sargramostim approved for?

It is FDA-approved for myeloid reconstitution after autologous or allogeneic transplant, for transplant engraftment failure or delay, after induction chemotherapy in older AML patients, for progenitor-cell mobilization, and for acute radiation syndrome.

Why is fluid retention a concern with GM-CSF?

GM-CSF can cause fluid retention, edema, and capillary-leak syndrome with pleural or pericardial effusions, so patients with cardiac or fluid-overload conditions are monitored closely.

What is a first-dose reaction?

Some patients experience flushing, low blood pressure, rapid heart rate, and shortness of breath with the first dose, which is why initial administration is medically supervised.

Is sargramostim a supplement or research peptide?

No. It is a prescription recombinant-protein biologic requiring clinical oversight, not an over-the-counter supplement or research chemical.

EMA-approvedaka GM-CSF, Leukine

Sargramostim — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Sargramostim (also known as GM-CSF) is a peptide catalogued under Immune (GM-CSF). Documented context: Bone marrow recovery. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Sargramostim?

Sargramostim is recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), a yeast-derived glycoprotein marketed as Leukine.

It is an FDA-approved prescription biologic used to promote myeloid reconstitution - after autologous or allogeneic bone-marrow/peripheral-blood stem-cell transplantation, in bone-marrow transplant engraftment failure or delay, following induction chemotherapy in older adults with acute myeloid leukemia, and for peripheral-blood progenitor-cell mobilization; it is also approved to increase survival in acute radiation syndrome.

Evidence is human, drawn mainly from randomized and early-phase transplant and leukemia trials.

How does Sargramostim work?

Sargramostim binds GM-CSF receptors to stimulate proliferation and differentiation of granulocyte and macrophage progenitors, broadening its myeloid activity beyond the neutrophil-focused effect of G-CSF.

This accelerates recovery of neutrophils and monocytes/macrophages after marrow-suppressing therapy or transplant.

What does the research say about Sargramostim?

Sargramostim after autologous bone-marrow transplantation for lymphoid malignancy shortened neutrophil recovery and reduced infections in a placebo-controlled trial. ^[1]
In older adults with acute myeloid leukemia, GM-CSF after induction chemotherapy accelerated neutrophil recovery in a randomized placebo-controlled study. ^[2]
GM-CSF supported myeloid engraftment after allogeneic bone-marrow transplantation in early-phase clinical trials. ^[3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer — Nemunaitis J et al., New England Journal of Medicine 1991. (Randomized placebo-controlled trial)
[2] A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (over 55 to 70 years of age) with acute myelogenous leukemia — Rowe JM et al., Blood 1995. (Randomized controlled trial)
[3] Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation — Nemunaitis J et al., Blood 1991. (Phase I/II trial)
[4] Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors — Nemunaitis J et al., Blood 1992. (Phase II trial)
[5] Use of growth factors during induction therapy for acute myeloid leukemia — Rowe JM et al., Leukemia 1996. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Sargramostim is a clinician-prescribed injectable dosed by body-surface area and given intravenously or subcutaneously, with timing tied to transplant, chemotherapy, or mobilization schedules.

This is context only and not a dosing recommendation; administration and monitoring (including fluid status and blood counts) are managed by the treating hematology/transplant team.

Side effects & safety profile

Common effects include bone/musculoskeletal pain, fever, rash, and injection-site reactions; a first-dose reaction with flushing, hypotension, tachycardia, and dyspnea can occur.

GM-CSF is particularly associated with fluid retention, peripheral edema, capillary-leak syndrome, and pleural or pericardial effusions, and can cause supraventricular arrhythmias; as with the CSF class, splenic enlargement occurs and splenic rupture is a rare reported risk.

It should not be given within 24 hours of chemotherapy or radiotherapy and is used cautiously in patients with cardiac, pulmonary, or fluid-overload conditions.

Stacking & combinations

In some transplant and mobilization protocols GM-CSF has been sequenced or combined with G-CSF or chemotherapy under specialist supervision, but this is a clinical decision, not a self-directed stack.

Finding Sargramostim vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

Sargramostim is GM-CSF and stimulates both granulocyte and macrophage lineages, whereas filgrastim is G-CSF and acts mainly on neutrophils; they have different approved uses and side-effect profiles.

References

[1] Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer — Nemunaitis J et al., New England Journal of Medicine 1991. PMID: 1903847. View sourceStudy: Randomized placebo-controlled trialGM-CSF sped neutrophil recovery and reduced infections and hospital stay after autologous BMT.
[2] A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (over 55 to 70 years of age) with acute myelogenous leukemia — Rowe JM et al., Blood 1995. PMID: 7605984. View sourceStudy: Randomized controlled trialGM-CSF after induction shortened neutropenia in older AML patients (ECOG E1490).
[3] Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation — Nemunaitis J et al., Blood 1991. PMID: 1902125. View sourceStudy: Phase I/II trialGM-CSF accelerated myeloid engraftment after allogeneic BMT.
[4] Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors — Nemunaitis J et al., Blood 1992. PMID: 1586709. View sourceStudy: Phase II trialGM-CSF supported hematopoietic recovery after unrelated-donor allogeneic BMT.
[5] Use of growth factors during induction therapy for acute myeloid leukemia — Rowe JM et al., Leukemia 1996. PMID: 8618471. View sourceStudy: Narrative reviewReviews trial evidence for CSFs including GM-CSF during AML induction.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.